Naphazoline/pheniramine

From WikiProjectMed
Jump to navigation Jump to search
Naphazoline/pheniramine
Combination of
PheniramineAntihistamine
Names
Trade namesNaphcon-A, Opcon-A, Visine-A, others
Clinical data
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
use		Eye drop
Defined daily dosenot established[1]
External links
AHFS/Drugs.comMultum Consumer Information
Legal
Legal status

Naphazoline/pheniramine, sold under the brand name Naphcon-A among others, is a combination eye drop used to help the symptoms of allergic conjunctivitis such as from hay fever.[2] It contains naphazoline and pheniramine.[2][3] It is used as an eye drop.[3] Use is not recommended for more than three days.[4]

Side effects may include allergic reactions, eye pain, and dilated pupils.[2][5][4] It is unclear if use in pregnancy is safe.[3] Nephazoline works by resulting in constriction of blood vessels thus decreasing redness well pheniramine works by blocking the effects of histamine to stop itching.[3]

The combination was approved for medical use in the United States in 1994.[6][7][3] It is available over the counter.[6][7][2] In 2017, it was the 203rd most commonly prescribed medication in the United States, with more than two million prescriptions.[8][7]

Medical use

It is administered topically with one to two drops applied to the affected eye(s) up to four times daily.[2]

Dosage

The defined daily dose is not established[1]

Side effects

Society and culture

Cost

In 2017, it was the 203rd most commonly prescribed medication in the United States, with more than two million prescriptions.[8][7]

  • Naphazoline/pheniramine costs (US)

    Naphazoline/pheniramine costs (US)

  • Naphazoline/pheniramine prescriptions (US)

    Naphazoline/pheniramine prescriptions (US)

References

  1. ↑ 1.0 1.1 "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 1 July 2021. Retrieved 9 September 2020.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 "Naphcon A- naphazoline hydrochloride and pheniramine maleate solution/ drops". DailyMed. 16 September 2019. Archived from the original on 28 August 2021. Retrieved 10 August 2020.
  3. ↑ 3.0 3.1 3.2 3.3 3.4 "Naphazoline and pheniramine ophthalmic Uses, Side Effects & Warnings". Drugs.com. Archived from the original on 19 April 2019. Retrieved 19 April 2019.
  4. ↑ 4.0 4.1 Kizior, Robert J.; Hodgson, Barbara B. (2014). Saunders Nursing Drug Handbook 2015 - E-Book. Elsevier Health Sciences. p. 163. ISBN 9780323280181. Archived from the original on 2020-04-16. Retrieved 2019-04-19.
  5. ↑ "Naphazoline/pheniramine ophthalmic Side Effects in Detail". Drugs.com. Archived from the original on 19 April 2019. Retrieved 19 April 2019.
  6. ↑ 6.0 6.1 "Naphcon-A: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 22 September 2020. Retrieved 19 April 2020.
  7. ↑ 7.0 7.1 7.2 7.3 "Naphazoline Hydrochloride; Pheniramine Maleate - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 11 April 2020.
  8. ↑ 8.0 8.1 "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.

External links

Retrieved from "https://mdwiki.org/w/index.php?title=Naphazoline/pheniramine&oldid=1393133"